Real-World Effectiveness, Safety, and Tolerability of Adjuvant CDK4/6 Inhibitor Therapy. (PubMed, Cureus) - Oct 7, 2026 - "In this retrospective non-randomized study, adding adjuvant abemaciclib or ribociclib to NSAI therapy was associated with two-year iDFS improvements in high-risk HR+/HER2- early breast cancer. However, after Bonferroni correction, the iDFS benefit remained statistically significant for abemaciclib and did not remain statistically significant for ribociclib. The therapies proved highly feasible and manageable in routine clinical practice."
Journal • Real-world evidence • Breast Cancer • Hematological Disorders • HER2 Breast Cancer • HER2 Negative Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Musculoskeletal Pain • Neutropenia • Oncology • Solid Tumor • HER-2
|
|
Apurva Patel; Harsha P Panchal; Kajal Shah; Rajan Yadav
|